You are using an unsupported browser.
Some features of this site may not function properly. For optimal user experience, please view this site in Chrome, Firefox, Safari, or Edge.

Xpert Xpress SARS-CoV-2 Test

News Releases

Cepheid to Webcast Upcoming Financial Presentations

SUNNYVALE, Calif., May 1, 2013 /PRNewswire/ -- Cepheid (NASDAQ: CPHD) today announced that its executives will be speaking at the following conferences, and invited investors to participate via webcast.

Robert W. Baird & Co. Growth Stock Conference, Chicago, IL
Thursday, May 9, 2013 at 8.35 a.m. Central Time

Bank of America Merrill Lynch Health Care Conference, Las Vegas, NV
Tuesday, May 14, 2013 at 3.40 p.m. Pacific Time

UBS Global Healthcare Conference, New York, NY
Wednesday, May 22, 2013 at 10.00 a.m. Eastern Time

Jefferies Healthcare Conference, New York, NY
Tuesday, June 4, 2013 at 10.00 a.m. Eastern Time

William Blair Growth Stock Conference, Chicago, IL
Wednesday, June 12, 2013 at 10.40 a.m. Central Time

Goldman Sachs Global Healthcare Conference, Rancho Palos Verde, CA
Thursday, June 13, 2013 at 10.00 a.m. Pacific Time

Accessing Live Webcasts

To access the live webcasts for these events, please visit Cepheid's website at at least 15 minutes before the scheduled start time to download any necessary audio or plug-in software.  A replay of the webcasts will be available shortly following the presentation and will remain available for at least 90 days.

About Cepheid

Based in Sunnyvale, Calif., Cepheid (Nasdaq: CPHD) is a leading molecular diagnostics company that is dedicated to improving healthcare by developing, manufacturing, and marketing accurate yet easy to use molecular systems and tests. By automating highly complex and time-consuming manual procedures, the company's solutions deliver a better way for institutions of any size to access the full power of molecular diagnostics. The company's systems enable rapid, sophisticated genetic testing for organisms and genetic-based diseases by automating otherwise complex manual laboratory procedures. Through its strong molecular biology capabilities, the company is focusing on those applications where accurate, rapid, and actionable test results are needed most, such as managing infectious diseases and cancer. For more information, visit


For Media Inquiries:  

For Investor Inquiries:

Jared Tipton 

Jacquie Ross

Cepheid Corporate Communications 

Cepheid Investor Relations

Tel: (408) 400-8377 

Tel: (408) 400-8329


SOURCE Cepheid

Back to Top